This is a study to assess the efficacy augmenting cognitive remediation therapy (CRT) with a
pharmacological agent for individuals with schizotypal personality disorder (SPD). Impaired
cognition, along with functional and social skill deficits, is a core feature of
schizophrenia and schizophrenia spectrum disorders. A better understanding of the cognitive
and functional impairments in schizophrenia-related conditions, as well as the identification
of interventions that can reduce these impairments, are vital to improving outcomes for
individual with these disorders.